EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NKCC1 : A key regulator of glioblastoma progression

Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner iD

Molecular Oncology · 2026-06 · 20 (6) · 1420-1428

DOI: 10.1002/1878-0261.70242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 24.03.2026. Verfasst von Anja Thomsen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jena University Hospital-Friedrich-Schiller University Jena, Jena, Germany. Hauptthemen laut MEDLINE: Solute Carrier Family 12, Member 2, Glioblastoma, Brain Neoplasms. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with poor prognosis despite multimodal therapy. Chloride cotransporters NKCC1 and KCC2 are key regulators of intracellular chloride levels and thereby determine whether GABA acts inhibitory or excitatory. In GBM, disrupted chloride homeostasis promotes proliferation, migration, and stem‐like properties, but its clinical relevance is not fully understood. We analyzed NKCC1 and KCC2 expression in GBM samples, considering clinical parameters, such as age, gender, and MGMT promoter methylation. Statistical analyses included ROC‐based cutoff determination, Kaplan–Meier survival analysis, and subgroup. Immunohistochemistry was performed to identify cell types expressing NKCC1. NKCC1 expression was significantly higher in older patients and emerged as a prognostic marker for recurrence‐free survival, with lower levels correlating with delayed recurrence, although overall survival was unaffected. NKCC1 was expressed in stem‐like, astrocytic, and neuronal progenitor cells, but not in mature neurons. These findings identify NKCC1 as a regulator of GBM progression and recurrence, linking chloride transporter imbalance to GABAergic signaling. Targeting NKCC1 and restoring chloride homeostasis may provide promising new treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Solute Carrier Family 12, Member 2GlioblastomaBrain NeoplasmsHumansFemaleSymportersDisease ProgressionMaleK Cl- CotransportersMiddle AgedGene Expression Regulation, NeoplasticAdultAged

Stichwörter der Autor:innen

GABAergic signalingKCC2chloride homeostasistumor recurrence

Substanzen

Solute Carrier Family 12, Member 2SymportersSLC12A2 protein, humanK Cl- Cotransporters

Autor:innen und Institutionen

  • Department of Neurology, Jena University Hospital-Friedrich-Schiller University Jena, Jena, Germany.
  • Department of Neurosurgery, Jena University Hospital-Friedrich-Schiller University Jena, Jena, Germany.
  • Experimental Trauma Surgery, Department of Trauma, Hand and Reconstructive Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
  • Jena Centre for Healthy Aging, Jena University Hospital, Jena, Germany.

ORCID-Profile: Silke Keiner

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Thomsen, A., Freitag, D., Haase, M., Senft, C., Schwarz, F., & Keiner, S. (2026). NKCC1 : A key regulator of glioblastoma progression. Molecular Oncology, 20(6), 1420-1428. https://doi.org/10.1002/1878-0261.70242

Vancouver

Thomsen A, Freitag D, Haase M, Senft C, Schwarz F, Keiner S. NKCC1 : A key regulator of glioblastoma progression. Molecular Oncology. 2026;20(6):1420-1428. doi:10.1002/1878-0261.70242

BibTeX
@article{Thomsen2026,
  author = {Thomsen, Anja and Freitag, Diana and Haase, Madlen and Senft, Christian and Schwarz, Falko and Keiner, Silke},
  title = {NKCC1 : A key regulator of glioblastoma progression},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {6},
  pages = {1420--1428},
  doi = {10.1002/1878-0261.70242}
}
Kostenlos starten →